35 completed, 6 terminated, 4 recruiting, 2 active not recruiting. 51 Phase 3, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Completed 35, Terminated 6, Recruiting 4, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 15 | Completed 12, Terminated 2, Unknown 1 |
Follow Bupropion: new trials by email Literature Review of Bupropion trials Research Report on Bupropion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo - Smoking Cessation | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 705 | 2026-08-27 | 2026-11-06 |
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder | Phase 3 | Terminated | Dr. Inge Winter | 1 | 2025-04-27 | 2026-11-05 |
| The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Escitalopram, Sertraline, Venlafaxine - Bipolar Depression | Phase 3 | Recruiting | Dr. Inge Winter | 418 | 2025-02-11 | 2025-09-26 |
| Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB - Methamphetamine-dependence, Methamphetamine Abuse | Phase 3 | Active not recruiting | National Institute on Drug Abuse (NIDA) | 360 | 2024-07-01 | 2026-07-13 |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy Inavolisib, Fulvestrant, Alpelisib - Breast Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 420 | 2023-06-07 | 2026-10-26 |
| Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment Bupropion - Smoking Cessation | Phase 3 | Recruiting | University of Kansas Medical Center | 500 | 2023-02-28 | 2026-02-23 |
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette Bupropion, Zonisamide, Placebo bupropion - Smoking Cessation | Phase 3 | Completed | Rose Research Center, LLC | 180 | 2021-12-14 | 2026-02-06 |
| Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya Bupropion, Positively smoke free, Brief advice to quit smoking - HIV, Smoking Cessation | Phase 3 | Completed | University of Maryland, Baltimore | 300 | 2020-08-01 | 2025-02-05 |
| Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes Zonisamide, Bupropion, Halo G6 e-cigarette - Smoking Cessation | Phase 3 | Completed | Rose Research Center, LLC | 26 | 2020-05-27 | 2022-04-13 |
| A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 3 | Withdrawn | Janssen-Cilag International NV | 2019-12-01 | 2025-04-27 | |
| Open-Label Safety Study of AXS-05 in Subjects With Depression AXS-05 (dextromethorphan and bupropion) oral tablets - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Completed | Axsome Therapeutics, Inc. | 876 | 2019-07-08 | 2022-10-12 |
| Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 3 | Active not recruiting | University of Rochester NCORP Research Base | 422 | 2019-06-27 | 2026-09-30 |
| Individualizing Pharmacotherapy for African American Smokers Nicotine patch, Varenicline Tartrate, Bupropion - Smoking Cessation | Phase 3 | Completed | University of Kansas Medical Center | 392 | 2019-05-01 | 2023-04-03 |
| Individualized Obesity Pharmacotherapy Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity | Phase 3 | Completed | Mayo Clinic | 193 | 2017-12-11 | 2023-07-18 |
| Addressing Dementia Via Agitation-Centered Evaluation AXS-05, Bupropion, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 2 / Phase 3 | Completed | Axsome Therapeutics, Inc. | 366 | 2017-07-13 | 2023-09-13 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder AXS-05, Bupropion - Treatment Resistant Major Depressive Disorder | Phase 3 | Completed | Axsome Therapeutics, Inc. | 312 | 2016-03-01 | 2021-03-24 |
| Web-based Smoking Cessation Program for Tribal College Students Internet-All Nations Breath of Life (I-ANBL), Honoring the Gift of Heart Health, Nicotine gum, Patch, or Lozenge or Zyban® or Chantix® - Smoking Cessation | Phase 3 | Completed | Won Choi, PhD, MPH | 251 | 2015-05-01 | 2021-12-07 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder Bupropion, Bupropion Matching Placebo, Escitalopram - Depressive Disorder, Major | Phase 3 | Completed | GlaxoSmithKline | 534 | 2015-02-10 | 2020-02-25 |
Showing 20 of 51. Sign in to see all of them.
Smoking Cessation (19) · Tobacco Use Disorder (11) · Smoking (9) · Depression (7) · Depressive Disorder, Major (6) · Obesity (4) · Cigarette Smoking (3) · Depressive Disorder, Treatment-Resistant (3) · Bipolar Disorder (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Overweight (2) · Schizophrenia (2) · Vaping (2) · Acute Coronary Syndrome (1)
Axsome Therapeutics, Inc. (4) · Duke University (4) · National Institute on Drug Abuse (NIDA) (4) · University of Kansas Medical Center (3) · Dr. Inge Winter (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · New York State Psychiatric Institute (2) · Rose Research Center, LLC (2) · University of California, San Francisco (2) · University of Minnesota (2) · Yale University (2) · Alliance for Clinical Trials in Oncology (1) · Altschuler, Eric, M.D. (1) · AstraZeneca (1)
United States (42) · Canada (5) · Germany (4) · Australia (3) · Belgium (2) · China (2) · France (2) · Italy (2) · Poland (2) · South Africa (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Austria (1)
Jed E Rose, Ph.D. (3) · Marc E Mooney, Ph.D. (2) · A. Daigneault, Dr. (1) · A. Ravindran, Dr. (1) · A. Schaffer, Dr. (1) · A.V. Mysore, Dr. (1) · Andres J Acosta (1) · B. Frey, Dr. (1) · Beth L Murphy, MD, PhD (1) · David Kalman, PhD (1) · Dorothy Hatsukami, PhD (1) · Edward F. Ellerbeck, MD, MPH (1) · Ellen R. Gritz, PhD (1) · Eric A Dedert, PhD (1)
PMID 37230961, PMID 37142273, PMID 34611902, PMID 41401709, PMID 16102908, PMID 16801293, PMID 17624979, PMID 18065851, PMID 18236294, PMID 18397444, PMID 18420774, PMID 18447101, PMID 18544464, PMID 19023824, PMID 19349629, PMID 19358791, PMID 19392908, PMID 19730273, PMID 19730274, PMID 19778993, PMID 19901150, PMID 21233256, PMID 22097928, PMID 22770436, PMID 23128154, PMID 23497790, PMID 23536105, PMID 23640009, PMID 23656848, PMID 23672772, PMID 24067192, PMID 24108148, PMID 24175721, PMID 24329972, PMID 24399554, PMID 24440324, PMID 24816198, PMID 24934962, PMID 25326910, PMID 26474010, PMID 27213949, PMID 29679432, PMID 30664539, PMID 33687070, PMID 33759389, PMID 36387983, PMID 37335995, PMID 37338906, PMID 37530824, PMID 39868569
K01DA019446 (2), P50DA027840 (2), 2018 (1), 2023 (1), K23DK071646 (1), R01CA101963 (1), R01CA138417 (1), R01CA174481 (1), R01CA214647 (1), R01DA002538 (1), R01DA011444 (1), R01DA013490 (1), R01DA017073 (1), R01DA017370 (1), R01DA024709 (1)